Overview of important clinical studies in relapsed/refractory PTCL and the representation of rare PTCL subtypes
| Investigational agent used . | Total number of patients . | EATL/MEITL n (best response) . | SPTCL n (best response) . | HSTCL n (best response) . | Responses in other/unspecified subtypes in publication . |
|---|---|---|---|---|---|
| Pralatrexate (Propel study, O’Connor et al)108 | 111 | 0 (0) | 0 (0) | 0 (0) | 3 tMF with response 3 "other" patients with response |
| Romidepsin (Coiffier et al)81 | 130 | 6 (0) | 3 (0) | 0 (0) | NA |
| Belinostat (Belief study, O’Connor et al)83 | 129 | 2 (0) | 0 (0) | 2 (0) | NA |
| Alisertib vs investigator’s choice (Lumiere study, O’Connor et al)109 | 271 | 6 pts total, 3 treated with alisertib, 3 with comparator (NR) | 1, treated with comparator (NR) | 0 (0) | 40 pts with “other” subtypes; ORR in “other” PTCL 32% and 38% for alisertib and comparator respectively |
| Duvelisib – (Pro et al. ASH 2020 and Zinzani et al)85 | 101 | 0 (0) | 1 (CR) | 0 (0) | 4 “other” lymphomas 2 responses seen |
| Ruxolitinib (Moskowitz et al)56 | 53 | 1 (1 patient from the γ/δ TCL group had PR) | 1 (SD) | 2 (1 patient from the γ/δ TCL group had PR) | NA γ/δ TCL group (4 pts) included 1 patient with PCTCL |
| Valemetostat (Horowitz et al.110) | 133 | 1 (NR) | 0 (0) | 0 (0) | 19 patients with “other” subtypes, ORR of 47.4% |
| Golidocitinib (Kim et al.111) | 51 | 2 (0) | 0 (0) | 0 (0) | NA |
| CD70 CAR-T (Iyer et al.112) | 15 | 0 (0) | 0 (0) | 0 (0) | NA |
| CD5 CAR-T (Hill et al.113) | 5 | NR | NR | NR | Responses seen in AITL and PTCL NOS |
| AUTO4 CAR T (Cwynarski et al.114) | 12 | 0 (0) | 0 (0) | 0 (0) | NA |
| AFM13 (Kim et al.115) | 108 | NR | NR | NR | 11 4 patients responded |
| Nivolumab (Bennani et al.116) | 12 | 1 (PR) | 0 (0) | 1 (Hyperprogression) | NA |
| Pembrolizumab (Barta et al.117) | 18 | 1 (Progression) | 0 (0) | 1 (SD) | NA |
| CD30 CAR-T (Vorhees et al.118) | 1 | 1 (CR) | 0 | 0 | NA |
| Investigational agent used . | Total number of patients . | EATL/MEITL n (best response) . | SPTCL n (best response) . | HSTCL n (best response) . | Responses in other/unspecified subtypes in publication . |
|---|---|---|---|---|---|
| Pralatrexate (Propel study, O’Connor et al)108 | 111 | 0 (0) | 0 (0) | 0 (0) | 3 tMF with response 3 "other" patients with response |
| Romidepsin (Coiffier et al)81 | 130 | 6 (0) | 3 (0) | 0 (0) | NA |
| Belinostat (Belief study, O’Connor et al)83 | 129 | 2 (0) | 0 (0) | 2 (0) | NA |
| Alisertib vs investigator’s choice (Lumiere study, O’Connor et al)109 | 271 | 6 pts total, 3 treated with alisertib, 3 with comparator (NR) | 1, treated with comparator (NR) | 0 (0) | 40 pts with “other” subtypes; ORR in “other” PTCL 32% and 38% for alisertib and comparator respectively |
| Duvelisib – (Pro et al. ASH 2020 and Zinzani et al)85 | 101 | 0 (0) | 1 (CR) | 0 (0) | 4 “other” lymphomas 2 responses seen |
| Ruxolitinib (Moskowitz et al)56 | 53 | 1 (1 patient from the γ/δ TCL group had PR) | 1 (SD) | 2 (1 patient from the γ/δ TCL group had PR) | NA γ/δ TCL group (4 pts) included 1 patient with PCTCL |
| Valemetostat (Horowitz et al.110) | 133 | 1 (NR) | 0 (0) | 0 (0) | 19 patients with “other” subtypes, ORR of 47.4% |
| Golidocitinib (Kim et al.111) | 51 | 2 (0) | 0 (0) | 0 (0) | NA |
| CD70 CAR-T (Iyer et al.112) | 15 | 0 (0) | 0 (0) | 0 (0) | NA |
| CD5 CAR-T (Hill et al.113) | 5 | NR | NR | NR | Responses seen in AITL and PTCL NOS |
| AUTO4 CAR T (Cwynarski et al.114) | 12 | 0 (0) | 0 (0) | 0 (0) | NA |
| AFM13 (Kim et al.115) | 108 | NR | NR | NR | 11 4 patients responded |
| Nivolumab (Bennani et al.116) | 12 | 1 (PR) | 0 (0) | 1 (Hyperprogression) | NA |
| Pembrolizumab (Barta et al.117) | 18 | 1 (Progression) | 0 (0) | 1 (SD) | NA |
| CD30 CAR-T (Vorhees et al.118) | 1 | 1 (CR) | 0 | 0 | NA |
AITL, angioimmunoblastic T-cell lymphoma CAR, chimeric antigen receptor; NA, not applicable; PR, partial remission; Pts, patients; SD, stable disease; NR, not reported.